摘要
非小细胞肺癌(non-small cell lung cancer, NSCLC)是肺癌的主要病理类型,大部分患者就医时已是晚期,其5年生存率约仅为15%。现阶段以免疫检查点抑制剂(Immune checkpoint inhibitor, ICI)作为代表的免疫治疗时代的到来为肺癌领域带来了革命性的突破,显著延长了肺癌患者的生存时间,已经成为非小细胞肺癌患者不可或缺的治疗手段。肺癌免疫治疗取得新突破的同时,免疫检查点抑制剂在肺癌治疗领域也有了更深层次的研究,因此,本文总结了不同时期非小细胞肺癌免疫检查点抑制剂治疗的研究现状,探讨了现阶段需应对的挑战,并指出了未来的研究前景。
Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, most patients with NSCLC are in advanced stage when they seek medical treatment, and their 5-year survival rate is only about 15%. The advent of the era of immunotherapy represented by immune checkpoint in-hibitor (ICI) has brought a revolutionary breakthrough in the field of lung cancer, significantly ex-tending the survival time of lung cancer patients, and has become an indispensable treatment for non-small cell lung cancer patients. With new breakthroughs in lung cancer immunotherapy, im-mune checkpoint inhibitors have also been further studied in the field of lung cancer treatment. Therefore, this review summarizes the research status of immune checkpoint inhibitors for NSCLC in different periods, discusses the challenges to be met at present, and points out the future re-search prospects.
出处
《临床医学进展》
2023年第8期12559-12570,共12页
Advances in Clinical Medicine
